MORRISTOWN, N.J., Jan 19, 2010 /PRNewswire via COMTEX/ -- In the news release, Watson Confirms Filing of FDA Application for Generic Lidoderm(R), issued Jan. 19 by Watson Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the first paragraph, second and third sentences should read "lidocaine topical patch 5%" rather than "lidocaine topical patch 8%" as originally issued inadvertently. The complete, corrected release follows:
Watson Confirms Filing of FDA Application for Generic Lidoderm(R)
Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its lidocaine topical patch 5% prior to the expiration of U.S. Patent No. 5,827,529. Watson's lidocaine topical patch 5% is a generic version of Endo's Lidoderm(R).
On January 15, 2010, pursuant to the Hatch-Waxman Act, Watson notified Endo's partners Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA that its ANDA requesting approval from the FDA for a generic version of Lidoderm(R) contained a paragraph IV certification asserting that the Lidoderm(R) patent is invalid, unenforceable and/or not infringed. Lidoderm(R) is indicated for relief of pain associated with post-herpetic neuralgia.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.
For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.
Statements contained in this press release that refer to Watson's estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Watson's product introductions and anticipated financial performance are forward-looking statements. It is important to note that Watson's goals and expectations are not predictions of actual performance. Watson's performance, at times, will differ from its goals and expectations. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the inherent uncertainty associated with financial projections; the impact of competitive products and pricing; the difficulty of predicting the timing or outcome of litigation; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson's and its third party manufacturers' facilities, products and/or businesses; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on Form 10-Q for the period ended September 30, 2009. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.
Lidoderm(R) is a registered trademark of Hind Healthcare, Inc.
SOURCE Watson Pharmaceuticals, Inc.